# Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD

Study · id `cardio:ct-nct05580510` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05580510](<https://clinicaltrials.gov/study/NCT05580510>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05580510

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

## Technical summary

Registry record NCT05580510. Randomized; no masking; primary purpose treatment. Start 2023-02-06 (anticipated); primary completion 2023-07-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT05580510, source copy `cardio:ctgov-nct05580510-2022-11-02`, retrieved 2026-10-26)
- Planned start: 2023-02-06 (anticipated) (ClinicalTrials.gov record NCT05580510, source copy `cardio:ctgov-nct05580510-2022-11-02`, retrieved 2026-10-26)
- Primary completion: 2023-07-28 (anticipated) (ClinicalTrials.gov record NCT05580510, source copy `cardio:ctgov-nct05580510-2022-11-02`, retrieved 2026-10-26)
- Completion: 2024-03-29 (anticipated) (ClinicalTrials.gov record NCT05580510, source copy `cardio:ctgov-nct05580510-2022-11-02`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT05580510, source copy `cardio:ctgov-nct05580510-2022-11-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05580510-2022-11-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- Condition: Congenital Heart Disease
- Condition: Heart Failure
- Condition: Heart Failure With Reduced Ejection Fraction
- Intervention (Drug): Sacubitril 49 MG / Valsartan 51 MG \[Entresto\] BID
- Intervention (Drug): Empagliflozin 10 MG OD
- Lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Adult congenital heart disease (`cardio:adult-congenital-heart-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez (`cardio:org-instituto-nacional-de-cardiologia-ignacio-chavez`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 61c65dadc8662500c043dad48ea34f23dd8dab65f8f13ef64f787529e3450b22
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
